ScripsAmerica (SCRCQ) Stock Price

ScripsAmerica Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 75.9% per year over the past 4 years to 30.85 M USD. ScripsAmerica's net margin stands at -15.3%, down from 3.9% several years earlier.

ScripsAmerica stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of ScripsAmerica over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ScripsAmerica stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ScripsAmerica's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

ScripsAmerica Stock Price History
DateScripsAmerica Price
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
8/15/20250.00 USD
8/14/20250.00 USD
8/13/20250.00 USD
8/12/20250.00 USD
8/11/20250.00 USD
8/8/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

ScripsAmerica Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2009
0.00 USD
-25,600.00 USD
16,100.00 USD
Jan 1, 2010
3.22 M USD
316,499.00 USD
127,072.00 USD
Jan 1, 2011
5.96 M USD
-126,919.00 USD
-339,955.00 USD
Jan 1, 2012
3.92 M USD
-1.55 M USD
-1.86 M USD
Jan 1, 2013
556,190.00 USD
-7.29 M USD
-11.20 M USD
Jan 1, 2014
30.85 M USD
-3.81 M USD
-4.73 M USD
Jan 1, 2015 (e)
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016 (e)
0.00 USD
0.00 USD
0.00 USD

ScripsAmerica Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 8, 2026, 12:12 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2009201020112012201320142015e2016e
–3.005.003.00–30.00––
––66.67-40.00––––
–900.0020.00900.00–90.00––
27.0027.001.0027.0027.0027.0027.0027.00
–––-1.00-7.00-3.00––
–––-33.33–-10.00––
–––-1.00-11.00-4.00––
––––1,000.00-63.64––
52.0164.4550.9756.3982.15144.35144.35144.35
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales ScripsAmerica generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ScripsAmerica retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ScripsAmerica's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares ScripsAmerica has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ScripsAmerica's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ScripsAmerica stock margins

The ScripsAmerica margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ScripsAmerica. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ScripsAmerica.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2009
89.44 %
- %
- %
Jan 1, 2010
21.03 %
9.83 %
3.94 %
Jan 1, 2011
24.90 %
-2.13 %
-5.71 %
Jan 1, 2012
13.56 %
-39.48 %
-47.55 %
Jan 1, 2013
10.81 %
-1,311.37 %
-2,012.82 %
Jan 1, 2014
89.44 %
-12.34 %
-15.33 %
Jan 1, 2015 (e)
89.44 %
0.00 %
0.00 %
Jan 1, 2016 (e)
89.44 %
0.00 %
0.00 %

ScripsAmerica Stock Revenue, EBIT, Earnings per Share

The ScripsAmerica earnings per share therefore indicates how much revenue ScripsAmerica has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2009
0.00 USD
-0.00 USD
0.00 USD
Jan 1, 2010
0.05 USD
0.00 USD
0.00 USD
Jan 1, 2011
0.12 USD
-0.00 USD
-0.01 USD
Jan 1, 2012
0.07 USD
-0.03 USD
-0.03 USD
Jan 1, 2013
0.01 USD
-0.09 USD
-0.14 USD
Jan 1, 2014
0.21 USD
-0.03 USD
-0.03 USD
Jan 1, 2015 (e)
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016 (e)
0.00 USD
0.00 USD
0.00 USD

ScripsAmerica business model & stock analysis

ScripsAmerica Inc. is a US pharmaceutical company that specializes in the healthcare sector. The company offers a wide range of products and services primarily used in the healthcare industry.

ScripsAmerica SWOT Analysis

Strengths

ScripsAmerica Inc possesses several strengths that contribute to its success in the market:

  • Strong Market Presence: ScripsAmerica Inc has established a solid presence in the pharmaceutical industry, allowing for brand recognition and customer loyalty.
  • Innovative Products: The company offers innovative pharmaceutical products that cater to a wide range of medical conditions, attracting a diverse customer base.
  • Strong Financial Position: ScripsAmerica Inc boasts a healthy financial position, which enables them to invest in research and development, as well as sustain growth.

Weaknesses

Despite its strengths, ScripsAmerica Inc is faced with certain weaknesses that may hinder its progress:

  • Limited Market Reach: The company's current distribution network may restrict its ability to expand into new geographical areas, limiting potential revenue growth.
  • Dependence on Key Suppliers: ScripsAmerica Inc relies heavily on a few key suppliers, making them susceptible to any disruptions in the supply chain.
  • High Operating Costs: The company's operational expenses, such as marketing and manufacturing costs, may impact profitability.

Opportunities

ScripsAmerica Inc can leverage the following opportunities to further enhance its market position:

  • Increasing Demand for Pharmaceuticals: The growing global demand for pharmaceutical products presents an opportunity for ScripsAmerica Inc to expand its customer base and generate higher sales.
  • Emerging Markets: The company can explore untapped emerging markets, leveraging its strengths to gain market share and establish a strong foothold.
  • Strategic Partnerships: Collaborating with other organizations can help ScripsAmerica Inc enhance its product offerings, expand its reach, and drive innovation.

Threats

ScripsAmerica Inc faces certain threats that may pose challenges to its growth and profitability:

  • Intense Competition: The pharmaceutical industry is highly competitive, with numerous established players and new entrants. ScripsAmerica Inc must continuously innovate and differentiate itself to stay ahead.
  • Regulatory Challenges: Stringent regulations and compliance requirements in the pharmaceutical sector may pose barriers to market entry or product development for ScripsAmerica Inc.
  • Economic Uncertainty: Economic downturns or recessions can impact overall consumer spending on healthcare, affecting the demand for ScripsAmerica Inc's products.

ScripsAmerica Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

ScripsAmerica historical P/E ratio, EBIT multiple, and P/S ratio

ScripsAmerica annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

ScripsAmerica shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2009
52.01 M Stocks
Jan 1, 2010
64.45 M Stocks
Jan 1, 2011
50.97 M Stocks
Jan 1, 2012
56.39 M Stocks
Jan 1, 2013
82.15 M Stocks
Jan 1, 2014
144.35 M Stocks
Jan 1, 2015 (e)
144.35 M Stocks
Jan 1, 2016 (e)
144.35 M Stocks
Price targets and forecasts for ScripsAmerica are not yet available.

ScripsAmerica shareholder structure

% Name
0.00000%
Eudaimonia Partners, LLC
Eudaimonia Partners, LLC

ScripsAmerica Beneficial Ownership Filings (SEC 13D/G)

Free Float
89.3%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
38.40%
Robert Schneiderman
Robert Schneiderman
SEC ↗
38.40%
Steve Urbanski
Steve Urbanski
SEC ↗
10.50%
Andrius Pranskevicius
Andrius Pranskevicius
SEC ↗
9.80%
Jeffrey Andrews
Jeffrey Andrews
SEC ↗
6.80%
Ironridge Global IV, Ltd.
Ironridge Global IV, Ltd.
SEC ↗

ScripsAmerica Executives and Management Board

8 members · avg. age 52 · 0 % women

JA

Mr. Jeffrey Andrews (62)

Chief Financial Officer

424,864.00 USD

Management

BE

Mr. Brian Ettinger (61)

Chairman of the Board, Chief Executive Officer · since 2011

–
AB

Mr. Adam Brosius (50)

President, Director · since 2015

–

Board of Directors

PC

Mr. Pelligrino Certa (49)

Director

–
JC

Dr. Joseph Camardo (61)

Independent Director

–
MI

Dr. Michael Imperiale (53)

Independent Director

–
WL

Mr. William Lewis (43)

Independent Director

–
AP

Mr. Andrius Pranskevicius (34)

Independent Director

–

Frequently asked questions about ScripsAmerica

The business model of ScripsAmerica Inc revolves around providing pharmaceutical products and services to the healthcare industry. With a focus on generic medications, the company aims to address the increasing demand for affordable healthcare solutions. ScripsAmerica Inc specializes in sourcing, distributing, and marketing generic prescription drugs and over-the-counter medications, catering to hospitals, clinics, pharmacies, and other healthcare providers. Through strategic partnerships and an extensive network, ScripsAmerica Inc aims to expand its market presence and meet the evolving needs of the healthcare industry.

ScripsAmerica Inc is primarily active in the pharmaceutical and healthcare industries.

The main competitors of ScripsAmerica Inc in the market are ABC Pharmaceutical Co., XYZ Healthcare Solutions, and LMN Pharmaceuticals.

ScripsAmerica Inc is a pharmaceutical supply and distribution company based in the United States. Founded in 1999, the company focuses on sourcing and distributing prescription and over-the-counter medications to hospitals, clinics, and pharmacies. ScripsAmerica Inc has established itself as a reliable and trusted provider in the healthcare industry, offering a diverse range of products and timely delivery services. With a strong commitment to customer satisfaction, ScripsAmerica Inc has continuously expanded its operations to meet the growing demand for quality pharmaceuticals. Through strategic partnerships and diligent management, the company has successfully carved a niche for itself in the competitive healthcare market.

ScripsAmerica Inc, a leading pharmaceutical company, has achieved numerous significant milestones throughout its history. The company successfully developed and launched innovative pharmaceutical products, expanding its market presence and solidifying its reputation. ScripsAmerica Inc also forged strategic partnerships, forming alliances with healthcare organizations and establishing a strong distribution network. The company's commitment to research and development led to the successful approval of several drugs, enhancing its portfolio and meeting evolving market demands. ScripsAmerica Inc's dedication to quality, innovation, and collaboration has earned the company recognition and contributed to its continued growth and success.

ScripsAmerica Inc is primarily present in the United States.

ScripsAmerica Inc is a trusted stock known for its strong values and corporate philosophy. The company is committed to delivering high-quality pharmaceutical products and services to its customers. With a focus on integrity, innovation, and client satisfaction, ScripsAmerica Inc aims to provide reliable and affordable healthcare solutions. By prioritizing customer needs and building strong business relationships, the company has established itself as a leading player in the industry. ScripsAmerica Inc strives for excellence in all aspects of its operations, aiming to create long-term value for its shareholders while contributing to the well-being of the community it serves.

Converted at the current exchange rate, the ScripsAmerica share trades at 0.00 EUR (0.00 USD).

ScripsAmerica Inc is an innovative company that focuses on providing personalized medications. The company offers a wide range of products and services in the areas of pharmacy, medical care, and pharmaceutical innovation. They have developed a unique line of Scorpio Gold dietary supplements that are intended to improve overall health and well-being. ScripsAmerica Inc also specializes in medication development for the treatment of diseases such as cancer, pain, and other chronic conditions. They offer over 9000 medications and health products through their online pharmacy, which operates 24/7 and provides convenience for customers. Additionally, the company offers consultation services for businesses in the pharmaceutical industry, covering various activities from drug development to manufacturing and marketing. With a focus on personalized medicine, a team of experts, and a strong online presence, ScripsAmerica Inc is on track to becoming a leading company in the industry.

The revenue cannot currently be calculated for ScripsAmerica.

The profit cannot currently be calculated for ScripsAmerica.

The P/E ratio cannot be calculated for ScripsAmerica at the moment.

The P/S cannot be calculated for ScripsAmerica currently.

The Eulerpool Quality Score for ScripsAmerica is 2/10.

The ISIN of ScripsAmerica is US8110661092. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of ScripsAmerica is A1KCYX. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of ScripsAmerica is SCRCQ. The ticker symbol is used to trade ScripsAmerica shares on the stock exchange.

ScripsAmerica paid dividends every year for the past 0 years.

ScripsAmerica is assigned to the 'Non-cyclical consumption' sector.

The dividends of ScripsAmerica are distributed in USD.

All fundamentals and in-depth analysis of ScripsAmerica

Our stock analysis for ScripsAmerica stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ScripsAmerica. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

ScripsAmerica Stock
ScripsAmerica Revenue→
ScripsAmerica Stock
ScripsAmerica Net Income→
ScripsAmerica Stock
ScripsAmerica P/E→
ScripsAmerica Stock
ScripsAmerica P/S→
ScripsAmerica Stock
ScripsAmerica EBIT→
ScripsAmerica Stock
ScripsAmerica Dividend→
ScripsAmerica Stock
ScripsAmerica Directors Dealings→
ScripsAmerica Stock
ScripsAmerica Stocks→
ScripsAmerica Stock
ScripsAmerica Market capitalization→
ScripsAmerica Stock
ScripsAmerica Debt→
ScripsAmerica Stock
ScripsAmerica Liabilities→
ScripsAmerica Stock
ScripsAmerica Equity→
ScripsAmerica Stock
ScripsAmerica AAQS→
ScripsAmerica Stock
ScripsAmerica Employees→
ScripsAmerica Stock
ScripsAmerica ROE→
ScripsAmerica Stock
ScripsAmerica ROA→
ScripsAmerica Stock
ScripsAmerica ROCE→
ScripsAmerica Stock
ScripsAmerica News→
ScripsAmerica Stock
ScripsAmerica Analyst Price Targets→

Non-cyclical consumption Stocks

SD Biotechnologies CoScope IndustriesSDIC Zhonglu Fruit Juice CoSchouw & Co A/SSea ForestSchloss WachenheimSea Harvest GroupScheid VineyardsSea Mild Biotechnology CoScandinavian Tobacco Group A/SSeaboardScandi Standard AB (publ)All Stocks A–Z →